Cancer最新文献

{"title":"Sexual health among Danish cancer survivors and individuals with no history of cancer: Baseline findings from the nationwide Project SEXUS cohort study","authors":"Cecilie H. Madsen MD,&nbsp;Christian Graugaard MD, PhD,&nbsp;Susanne O. Dalton MD, PhD,&nbsp;Mikael Andersson MSc,&nbsp;Pernille E. Bidstrup MSc, PhD,&nbsp;Morten Frisch MD, PhD, DScMed","doi":"10.1002/cncr.70074","DOIUrl":"10.1002/cncr.70074","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Being diagnosed with and treated for cancer often results in physical symptoms and psychosocial distress that may affect sexual health. This population-based study in Denmark aimed to compare the sexual health of cancer survivors across multiple cancer sites with that of individuals with no history of cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were used from 4085 cancer survivors and 58,590 individuals without cancer aged 15 to 89 years, who participated in the nationally representative <i>Project SEXUS</i> cohort study. Prevalence estimates for sexual outcomes were calculated, and logistic regression analyses yielded confounder-adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for associations of cancer survivorship with sexual outcomes, both overall and across cancer sites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cancer survivors experienced significantly more sexual challenges than individuals without cancer, both overall and in the first 5 years after their most recent cancer diagnosis. This difference was seen across multiple cancer sites and regardless of age at diagnosis (&lt;60 vs. ≥60 years). Among several statistically significant findings, particularly high aORs were noted for dissatisfaction with breast appearance (aOR: 1.89; CI, 1.49–2.41) and genital pain dysfunction (aOR: 1.74; CI, 1.32–2.28) among women and lack of sexual needs (aOR: 1.93; CI, 1.61–2.30) and erectile dysfunction (aOR: 2.79; CI, 2.30–3.38) among men.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Compared to individuals with no history of cancer, sexual health was significantly affected among cancer survivors of both sexes and across cancer sites, time since diagnosis, and age at diagnosis. Health care professionals should recognize and routinely address the sexual challenges experienced by cancer survivors to enhance their biopsychosocial recovery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant immunochemotherapy for nonsurgical HPV-negative head and neck cancer","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.70036","DOIUrl":"10.1002/cncr.70036","url":null,"abstract":"&lt;p&gt;Giving immunotherapy with chemotherapy before radiation to nonsurgical patients with locoregionally advanced human papillomavirus (HPV)–negative head and neck cancer may improve treatment efficacy according to the phase 2, nonrandomized De-Escalation Therapy for Human Papillomavirus Negative Disease trial published in &lt;i&gt;JAMA Oncology&lt;/i&gt;.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In this trial of 36 nonsurgical patients with stage IVa/b HPV-negative head and neck squamous cell carcinoma, 53% of the patients had a deep response (i.e., &gt;50% tumor shrinkage per the Response Evaluation Criteria in Solid Tumors) after receiving neoadjuvant nivolumab plus chemotherapy (carboplatin and paclitaxel) before radiation. The deep response rate after neoadjuvant nivolumab plus chemotherapy met the primary endpoint of an improvement over the historical control of induction chemotherapy alone. Of the full cohort, 86% achieved an objective response (≥30% tumor shrinkage).&lt;/p&gt;&lt;p&gt;Investigators also tested the ability to de-escalate the radiation dose and volume among the deep responders after neoadjuvant immunochemotherapy. Compared to the 16 patients who were assigned to standard chemoradiation, the 19 patients who received de-escalated chemoradiation had fewer acute toxic effects during treatment and fewer distant metastases.&lt;/p&gt;&lt;p&gt;“Taken together, this suggests that neoadjuvant immunochemotherapy may improve outcomes in locoregionally advanced HPV-negative head and neck cancer, while also selecting patients who can do well with lower doses and volumes of radiation, which can lead to fewer side effects,” says the lead author of the study, Ari Rosenberg, MD, an oncologist and assistant professor of medicine at the University of Chicago Medicine who specializes in immunotherapy and other treatments for head and neck and thyroid cancers.&lt;/p&gt;&lt;p&gt;Programmed death ligand 1 (PD-L1) was a predictive biomarker for a response to chemoimmunotherapy and survival. Progression-free survival at 24 months was 88% for patients with PD-L1 expression with a combined positive score (CPS) of 20 or more but 59% for patients with PD-L1 expression with a CPS of less than 20 (&lt;i&gt;p&lt;/i&gt; = .16). The overall survival rates were 88% and 69%, respectively.&lt;/p&gt;&lt;p&gt;He says that the study builds on data from the KEYNOTE-689 study, which showed improved event-free survival with neoadjuvant immunotherapy for patients with surgically treated head and neck cancer. The phase 3 study found that the addition of neoadjuvant pembrolizumab to the standard of care (surgery and adjuvant radiotherapy with or without concomitant cisplatin) resulted in improved event-free survival at 36 months in comparison with the standard of care alone (57.6% vs. 46.4%; &lt;i&gt;p&lt;/i&gt; = .008). The study also found a significant improvement in event-free survival for patients whose tumors expressed PD-L1 with a CPS of 10 versus those treated with the standard of care alone (59.8% vs. 45.9%; &lt;i&gt;p&lt;/i&gt; = .004).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking prestige and dependency in global oncology","authors":"Saroj Niraula MBBS, MD, MSc, FRCPC","doi":"10.1002/cncr.70087","DOIUrl":"10.1002/cncr.70087","url":null,"abstract":"&lt;p&gt;Global oncology has made substantial progress over the past two decades. Childhood cancer survival has improved in many low- and middle-income countries (LMICs), diagnostic and treatment infrastructure has expanded, and cancer has become a global health priority alongside infectious diseases.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; These gains reflect the efforts of LMIC health systems, often supported by international partnerships.&lt;/p&gt;&lt;p&gt;Despite these improvements, a gap persists between global oncology’s potential and its reality, which are maintained by persistent structural and cultural patterns. Global health still operates in a hierarchical manner where institutions in high-income countries (HICs) retain control over funding, recognition, and agenda setting, whereas LMIC actors remain constrained by externally imposed standards and power dynamics.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Although this structure may sometimes have led to improvements in measured outcomes, it also sustains dependency across research, training, and health financing. In countries like Uganda, disruptions in foreign aid have jeopardized access to essential treatments, revealing the fragility of donor-reliant systems.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Recent US funding cuts to the Global Alliance for Vaccine and Immunization and to the World Health Organization further illustrate how political shifts in donor countries can destabilize LMIC programs.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt; Addressing these legacies requires not only resources and technology but fidelity to patients and systems: a foundation that endures beyond shifting agendas and political turns. When survival depends on visibility rather than durability, institutions adapt in ways that subvert priorities. These imbalances foster a form of structural corruption, propelled by the universal impulse to seek prestige and influence.&lt;/p&gt;&lt;p&gt;Ambition and prestige can be productive, and desirable, when aligned with equal opportunities for patients. In global health, these opportunities become problematic when they dictate priorities according to misaligned, external definitions of success. International partnerships offer resources and visibility, and at their best, can build capacity that endures beyond the partnership itself. However, when partnerships are designed to impress external audiences, they risk privileging symbolic achievement over local relevance. They impose foreign agendas, encourage unhealthy competition within LMICs for resources and recognition, and rely on unprepared HIC visiting delegations at the expense of long-term needs.&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Several years ago during my first job at Bhaktapur Cancer Hospital in Nepal, a donor from New Zealand gifted a radiotherapy machine to replace a 50-year-old cobalt unit. A large celebration followed. The donor was revered, the hospital leadership celebrated for securing a legacy, and a costly bunker was built at local expense. The machine itself never operated, presumably alread","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pragmatic randomized controlled pilot trial of brief meaning-centered psychotherapy in home care","authors":"Rebecca M. Saracino PhD,&nbsp;Ellen Y. Park BA,&nbsp;Hayley Pessin PhD,&nbsp;Nicole Onorato MPH,&nbsp;Margaret V. McDonald MSW,&nbsp;Caraline Demirjian MPH,&nbsp;Elizabeth Schofield PhD,&nbsp;Barry Rosenfeld PhD,&nbsp;William Breitbart MD,&nbsp;Allison J. Applebaum PhD","doi":"10.1002/cncr.70082","DOIUrl":"10.1002/cncr.70082","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Individuals with advanced cancer receiving home health care experience elevated psychosocial and existential distress, yet few interventions address these concerns. This pilot randomized controlled trial examined the feasibility, acceptability, and preliminary efficacy of brief, nurse-delivered, meaning-centered psychotherapy in patients with advanced cancer compared with treatment as usual (TAU).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Distressed patients (aged 18 years and older) were randomized 1:1 to receive either a three-session Meaning-Centered Psychotherapy for Hospitals, Hospice, and Home (MCP-H; <i>n</i> = 33) or TAU (<i>n</i> = 32). Feasibility was based on recruitment, retention, data completion, fidelity, and intervention engagement. Acceptability was based on patients’ and nurses’ ratings of MCP-H satisfaction. Preliminary efficacy was determined by changes in scores from baseline (T1) to 6 weeks (T2) and 10 weeks (T3) in meaning, and secondary outcomes were assessed using between-group analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-one patients enrolled. Feasibility was demonstrated by satisfactory recruitment (75% approach-to-consent rate; 92% enroll-to-randomize rate), retention (74% and 75% at T2 and T3, respectively), intervention engagement (94% completed 100% of the sessions), and treatment adherence (87% mean rating). Participants endorsed the intervention’s acceptability (96% satisfied or very satisfied). MCP-H participants experienced improvements in meaning using the Cohen's d (d = 0.59 at T2; d = 0.39 at T3) and most other secondary psychosocial outcomes at 6 and 10 weeks compared with TAU participants.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>MCP-H is feasible and acceptable among patients with advanced cancer in home care. This intervention demonstrated promising evidence of clinical efficacy. A larger, fully powered randomized controlled trial is needed to test the efficacy of the intervention for patients, nurses, and health system outcomes against an active control group.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 3P-CP model: Expanding our conceptualization of cancer pain","authors":"Desiree R. Azizoddin PsyD,&nbsp;Jian Zhao PhD,&nbsp;Tamara J. Somers PhD,&nbsp;Sarah E. Taylor MD, PhD,&nbsp;Joseph G. Winger PhD,&nbsp;Susan G. Dorsey PhD, RN, FAAN,&nbsp;Sarah Orris BS,&nbsp;Anaanya Nasta BA, BS,&nbsp;Yael Schenker MD, MAS, FAAHPM,&nbsp;Jessica S. Merlin MD, PhD, MBA,&nbsp;Heather S. L. Jim PhD,&nbsp;Kristin L. Schreiber MD, PhD,&nbsp;Hailey W. Bulls PhD","doi":"10.1002/cncr.70080","DOIUrl":"10.1002/cncr.70080","url":null,"abstract":"<p>Cancer pain is a complex, multifactorial, and growing public health challenge affecting millions of Americans. Effective pain management is essential for comprehensive cancer care, influencing physical and mental health, quality of life, and functional ability. However, progress in cancer pain management is hindered by the complexity of the issue and a fragmented understanding of the myriad factors shaping the pain experience. Additionally, traditional pain terminology—“acute” (&lt;6 months) and “chronic” pain (≥6 months)—offers limited utility in cancer contexts, highlighting the need for a more nuanced framework. To address this gap, we propose the 3P-CP model, which conceptualizes cancer pain through three interconnected phases: predisposing factors that increase cancer pain risk, precipitating factors that trigger cancer pain onset, and perpetuating factors that sustain or exacerbate cancer pain over time. This model provides a structured approach to assess the dynamic nature of cancer pain across the entirety of the cancer trajectory. In this paper, key factors associated with each phase of the 3P-CP model are outlined and their implications for research and clinical care explored. Aligning with the oncology field's shift toward precision medicine, the 3P-CP model has the potential to guide comprehensive assessment, risk mitigation, prevention, and intervention strategies—supporting efforts to deliver the right targeted and tailored treatments, to the right patients, at the right time.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of geographic variation in the incidence of adult nonmalignant meningioma in the United States, 2010–2019","authors":"Diana R. Withrow PhD,&nbsp;Joseph Boyle PhD,&nbsp;Martha S. Linet MD, MPH,&nbsp;Christine A. Pittman Ballard MPH,&nbsp;Gino Cioffi MPH,&nbsp;Carol Kruchko BA,&nbsp;Donald L. Miller MD,&nbsp;Valentina I. Petkov MD, MPH,&nbsp;Mackenzie Price MPH,&nbsp;Kristin Waite PhD,&nbsp;Quinn T. Ostrom PhD,&nbsp;Jill S. Barnholtz-Sloan PhD","doi":"10.1002/cncr.70042","DOIUrl":"10.1002/cncr.70042","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>US incidence rates of nonmalignant brain tumors are 3-fold higher in highest versus lowest incidence states. A county-level analysis was conducted to assess whether geographic variation in nonmalignant meningioma (NMM) incidence is related to demographics, cancer registry, health care, and other factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Age-adjusted incidence rates of NMM in US counties during 2010–2019 were modeled with data from the Central Brain Tumor Registry of the United States. Demographic, geographic, cancer registry, environmental, health care, health, lifestyle, and socioeconomic factors at the county level were drawn from numerous data sources. Bayesian index regression models were fit containing spatial random effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three domains were significantly associated with rates of NMM at the county level: cancer registry practices (funding source and % radiographically confirmed), socioeconomic status index (higher levels with percent working in white-collar occupations as an important contributor), and demographics (% Black and % female). No associations were observed for general health or environmental factors. In the fully adjusted model, the number of counties with significantly elevated and lowered spatial random effects decreased by 33% and 28%, respectively, compared to a no-covariate model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although general health and environmental factors cannot be ruled out in explaining the geographic variation in NMM incidence rates, results suggest that socioeconomic factors, certain demographic characteristics, and cancer diagnosis and registry practices may all play a significant role in driving such variation. These results may have implications for other tumor types diagnosed primarily radiographically or outside hospital settings, where variation in detection and reporting may affect incidence rates.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma","authors":"Shuai Tan MD, PhD,&nbsp;Huizhen He MS,&nbsp;Jing Ni MD, PhD,&nbsp;Yixian Guo MD, PhD,&nbsp;Huanyuan Wang MS,&nbsp;Zehao Cai MD,&nbsp;Mingyue Shang MS,&nbsp;Yaofang Cao MS,&nbsp;Yumeng Li MS,&nbsp;Yaochi Chen MS,&nbsp;Hong Zhao MS,&nbsp;Li Su MD, PhD,&nbsp;Ronghua Hu MD, PhD,&nbsp;Xiaoli Chang MD, PhD,&nbsp;Wanling Sun MD, PhD","doi":"10.1002/cncr.70083","DOIUrl":"10.1002/cncr.70083","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Central nervous system lymphoma (CNSL) is aggressive, and treatment with Bruton tyrosine kinase (BTK) inhibitors (BTKis) plays a key role. For this systematic review and meta-analysis, the authors evaluated BTKis for the treatment of primary CNSL (PCNSL) and secondary CNSL (SCNSL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>By May 1, 2025, the authors conducted a systematic search of databases, including PubMed, EMBASE, etc. Included studies were those that investigated BTKi-treated CNSL and analyzed the overall response rate (ORR) as well as the complete response (CR) and partial response (PR) rates using systematic review and meta-analysis software.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty studies (935 patients) were included in the meta-analysis. The pooled ORR and CR and PR rates were 73%, 49%, and 28%, respectively. The pooled ORR and CR rates for BTKi monotherapy were 60% and 34%, respectively; whereas the rates for BTKi plus chemotherapy or immunochemotherapy were 79% and 55%, respectively. For PCNSL, the pooled ORR and PR rates were 73% and 49%, respectively. For SCNSL, the pooled ORR and CR rates reached 75% and 53%, respectively. Among patients with PCNSL, zanubrutinib achieved pooled ORR and CR rates of 85% and 54%, respectively. Ibrutinib had pooled ORR and CR rates of 67% and 46%, respectively; whereas orelabrutinib demonstrated pooled ORR and CR rates of 70% and 59%, respectively. For SCNSL, zanubrutinib achieved pooled ORR and CR rates of 77% and 62%, respectively; whereas ibrutinib achieved rates of 72% and 54%, respectively. Hematologic toxicities and transaminase increases were grade 3–5 toxicities according to common toxicity criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The combination of BTKis with traditional chemotherapy or immunochemotherapy offers superior response rates compared with BTKis alone, and the safety profile is acceptable. Efficacy varies by BTKi type and should be selected based on patient condition. Specifically, for PCNSL, the response rates of zanubrutinib and obinutuzumab are better; for SCNSL, there is a minimal difference in efficacy among the various BTKis; and, overall, regardless of whether it is PCNSL or SCNSL, the off-target effects and side effects of covalent BTKis (zanubrutinib, obinutuzumab), except for ibrutinib, have improved.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening","authors":"Joelle T. Fathi DNP,&nbsp;Paul M. Cinciripini PhD,&nbsp;Madeline J. DePrimo BA,&nbsp;Thomas P. Houston MD,&nbsp;Hasmeena Kathuria MD,&nbsp;Elyse R. Park PhD,&nbsp;Bradley B. Pua MD,&nbsp;Theresa M. Roelke MSN,&nbsp;Kathryn L. Taylor PhD,&nbsp;Benjamin A. Toll PhD,&nbsp;Steve Zeliadt PhD,&nbsp;Ella A. Kazerooni MD, MS,&nbsp;Robert A. Smith PhD,&nbsp;Jamie S. Ostroff PhD","doi":"10.1002/cncr.35972","DOIUrl":"10.1002/cncr.35972","url":null,"abstract":"<p>Tobacco use is the primary contributor to disease and death in the United States, and cigarette smoking is the leading risk factor for lung cancer. Safe and effective treatments for tobacco dependence exist; however, access to and use of tobacco treatment remains low. The most recent Centers for Medicare and Medicaid Services National Coverage Determination requires a shared decision-making visit for lung cancer screening that includes counseling on the importance of maintaining cigarette smoking abstinence if a person formerly smoked; or the importance of smoking cessation if a person currently smokes and, if appropriate, furnishing of information about tobacco-cessation interventions. The directive is not well defined and provides little guidance for delivering high-quality cessation services. Effective integration of best practices for tobacco treatment in the context of lung cancer screening must extend far beyond recommendations to quit, patient literature to reinforce quitting, and available evidence-based treatments. To optimize the provision of tobacco treatment and improve health outcomes in people being screened for lung cancer, the American Cancer Society National Lung Cancer Roundtable Tobacco Treatment in the Context of Lung Cancer Screening Task Group recommends: (1) specify quality indicators and document tobacco treatment delivery; (2) embed tobacco treatment in lung cancer screening; (3) advocate for increased access to tobacco treatment; (4) build and train lung cancer screening staff; (5) provide full coverage of treatment medications; (6) leverage electronic health records to improve the provision of cessation services to lung cancer screenees; and (7) identify and address contextual barriers to incorporating tobacco treatment guidelines in screening.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35972","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145021993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma","authors":"Sean J. Judge MD,&nbsp;Emily Manin MD,&nbsp;Joanne Chou MPH,&nbsp;Robert J. Torphy MD,&nbsp;Caitlin A. McIntyre MD,&nbsp;Vinod P. Balachandran MD,&nbsp;Michael I. D’Angelica MD,&nbsp;Jeffrey A. Drebin MD,&nbsp;Mithat Gönen PhD,&nbsp;William R. Jarnagin MD,&nbsp;T. Peter Kingham MD,&nbsp;Eileen M. O’Reilly MD,&nbsp;Wungki Park MD,&nbsp;Alice C. Wei MD,&nbsp;Alice Zervoudakis MD,&nbsp;Kevin C. Soares MD","doi":"10.1002/cncr.70088","DOIUrl":"10.1002/cncr.70088","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The influence of obesity and sex on outcomes in pancreatic adenocarcinoma (PDAC) remains unclear. The association between obesity (body mass index [BMI], ≥30) and biologic sex (male or female) for outcomes in patients with PDAC undergoing a surgery-first approach was investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospectively maintained pancreatic cancer database at the Memorial Sloan Kettering Cancer Center was queried to identify all patients undergoing surgery with a pathologic diagnosis of PDAC. Clinicodemographic variables, outcomes, and tumor mutational analyses for all available patients were collected. Cumulative incidence of first recurrence involving the liver was estimated via a cumulative incidence function. Multivariable Cox regression was used to investigate the association between BMI and sex for overall survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 2012 to 2022, 939 patients were identified who underwent surgery with a final pathologic diagnosis of PDAC. Median age was 70 years, 52% were male, and 24% were obese (BMI, ≥30). When dichotomized by sex and obesity status (BMI, &lt;30 or ≥30), females with obesity had the lowest cumulative incidence of liver recurrence at 12 and 24 months postsurgery compared to all other groups (13% [95% CI, 7.2%–20%] and 15% [8.7%–23%], respectively). Females with obesity had the longest median overall survival at 37 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>After curative surgery for pancreatic cancer, females with obesity have a significantly lower rate of liver recurrence and the longest median overall survival. This does not appear to be related to surgical quality, receipt of adjuvant therapy, or tumor mutational profile. Investigation into host immune, metabolic, and hormonal parameters is paramount to understanding these differences.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival","authors":"Alissa J. Cooper MD,&nbsp;Edoardo Garbo MD,&nbsp;Andrea Arfe PhD,&nbsp;Michael Conroy MB, BCh, Bao,&nbsp;Narek Shaverdian MD,&nbsp;Matthew Bott MD,&nbsp;Teresa Gorria MD,&nbsp;Federica Pecci MD,&nbsp;Mihaela Aldea MD, PhD,&nbsp;Valsamo Anagnostou MD, PhD,&nbsp;Adam Schoenfeld MD,&nbsp;Daniel Gomez MD, MBA,&nbsp;Patrick M. Forde MBBCh,&nbsp;Mark M. Awad MD, PhD,&nbsp;David R. Jones MD,&nbsp;Biagio Ricciuti MD, PhD,&nbsp;Jamie E. Chaft MD","doi":"10.1002/cncr.70081","DOIUrl":"10.1002/cncr.70081","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors analyzed records of patients with stage IB–III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions. Clinical, demographic, and pathologic factors were incorporated in univariable and multivariable regression models to identify associations with outcomes (resection status, pathologic complete response [pCR], and subsequent event-free survival [EFS]) after standard-of-care neoadjuvant chemoIO.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Analyses included 115 patients, of whom 63% had stage III disease, 77% completed three cycles of chemoIO, and 78% underwent surgical resection. Ages older than 72 years versus 64 years and younger were associated with not proceeding to surgery in univariable (<i>p</i> = .006) and multivariable (<i>p</i> = .014) regression analyses. Nineteen patients (17%) had tumors with a pCR, and 34 (30%) had a major pathologic response. Positive programmed death-ligand 1 (PD-L1) expression (≥50%; vs. negative PD-L1 expression: odds ratio, 12.1; 95% confidence interval, 2.0–73.7; <i>p</i> = .007) and <i>KRAS</i> mutations (vs. wild-type <i>KRAS</i>: odds ratio, 3.9; 95% confidence interval, 1.07–14.4; <i>p</i> = .039) were associated with a higher probability of pCR in univariable analysis. The median event-free survival was not reached and did not differ among subgroups stratified by key clinical variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The results from this study confirm the trial experience of high pCR rates after neoadjuvant chemoIO. This supports the use of chemoIO irrespective of <i>KRAS</i> mutation status, PD-L1 expression, and histology, but suggests that this approach may be less suitable for older patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 18","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}